Circulating Tumor Cells segmentation by types categorizes the technologies used to isolate and analyze CTCs, principally into enrichment‑based, label‑free, microfluidic, and molecular‑detection platforms. Enrichment‑based methods rely on physical or immunoaffinity capture; sub‑types include size‑based filtration, density gradient centrifugation, and EpCAM‑targeted magnetic beads, collectively accounting for roughly 40 % of device sales due to their established clinical validation. Label‑free approaches exploit intrinsic biophysical properties such as dielectric susceptibility or acoustic forces, representing about 20 % of the market and appealing to laboratories seeking reagent‑free workflows. Microfluidic systems integrate precise fluid dynamics with antibody patterns or nanostructured surfaces, driving 25 % of revenue as they enable high‑throughput, low‑volume processing. Molecular‑detection platforms—primarily PCR‑based or next‑generation sequencing assays—quantify CTC‑derived nucleic acids, contributing the remaining 15 % and supporting companion‑diagnostic development. The relative share of each type reflects trade‑offs among sensitivity, scalability, cost, and regulatory clearance, thereby shaping the overall market size and investment focus. Regulatory pathways differ, with enrichment‑based devices often cleared via 510(k) submissions, whereas molecular platforms typically pursue de novo or PMA routes, influencing time‑to‑market and pricing structures.
